Chemokines are key controllers of cell trafficking and are involved in numerous pathological and inflammatory conditions. However, the fate of a chemokine ligand, once it is endocytosed with its receptor, remains obscure. Here, using chemokinetumor antigen fusion constructs, we demonstrate for the first time that chemokines are internalized to early/late endosomal and lysosomal compartments through a clathrindependent process and subsequently delivered to the cytosol for proteasomal processing, facilitating efficient cross-presentation to the TAP-1-dependent MHC class I processing pathway. These data not only elucidate the intracellular fate of chemokine ligands upon receptor uptake, but also demonstrate the superior carrier potency of chemokines for delivering self-antigens to both Class I and II processing pathways to induce CD8 + and CD4 + T cell responses.
Introduction
Heterotrimeric G-protein coupled seven-transmembrane-domain chemokine receptors (GPCRs) play a pivotal role in both homeostatic cell trafficking and a wide variety of inflammatory processes 1, 2 . Immature DC (iDC) are recruited to the periphery or to sites of inflammation and infection through preferentially expressed chemokine receptors, including CCR1, CCR2, CCR5 and CCR6 3, 4 . Chemokines upon receptor ligation induce phosphorylation and endocytosis of chemokine receptors through clathrin-coated vesicles utilizing β-arrestin adaptors 5, 6 , although viral chemokine receptors, such as US28, are endocytosed independently of β-arrestins 7 . The internalized receptors are subsequently dephosphorylated and recycled back to the cell surface or targeted for degradation 5, 6, 8 . CCR5 has been transported to early endosomes and subsequently recycled to the cell surface bypassing the Golgi apparatus and late endosomes, and this process does not involve protein synthesis 6 .
Moreover, the fate of the internalized receptor and the bound ligand may actually be regulated by the strength of the ligand-induced signaling or the nature of the ligand itself. For example, CCR5 is endocytosed through clathrin-coated vesicles upon binding to RANTES or AOP-RANTES, and although the latter drives CCR5 to a degradation pathway, RANTES-bound CCR5 is recycled to the cell surface 6 . While 15 . In the present study, we provide direct evidence that chemokine receptors do indeed deliver antigens to the MHC class I processing pathway and facilitate TAP-1 dependent antigen crosspresentation to CD8 + T cells. These data not only demonstrate the usefulness of chemokines in the development of cancer vaccines 11, 12 , which requires induction of effective CD4 + and CD8 + T cell responses against non-or weakly immunogenic selftumor antigens, but also provides new insight into the biology of chemokine and chemokine receptor interactions.
Materials and Methods

Fusion gene cloning and plasmid construction
Cloning strategy for murine MIP3α/CCL20, murine β-defensin 2 (mDF2β) and MC148 was previously described 11, 12 . The truncated human gp100 DNA fragment (a generous gift from Dr.Paul Robins, NCI/NIH, GeneBank # P40967) corresponding to residues from 22 -236 a.a. was cloned using primers PRhPmel17-1, ATACATATGCTCGAGGCTAGAAAAGTACCCAGAAACCA, and PRhPmel17-R1, AAAAGATCTCTCTAGATTTCTCAGGAAGTGCTTGT. Murine OFA-iLRP, (GeneBank # AF140348) was cloned from murine A20 B cell lymphoma (American Type Culture Collection, (ATCC) Manassas, VA) using the primers PRmOFA-1, CATACCATGGTCGACGGAGCCCTTGACGTCCTGCAG, and PRmOFA-R1,
TTAGGATCCGGACCACTCAGTGGTGGCT. All constructs were verified by the DNA sequencing (Fidelity Systems, Inc., Gaithersburg, MD).
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Recombinant fusion proteins and peptides
Fusion proteins were purified from inclusion bodies as described previously 11, 16 . The integrity and purity (>90%) of recombinant proteins were tested by SDS-PAGE under reducing conditions and Western blot hybridization with 9E10 anti-c-myc mAb (Sigma).
The peptides human-gp100 [25] [26] [27] [28] [29] [30] [31] [32] [33] Tap1<tm1Arp>/J (TAP-1 gene knock out) mice were purchased from Jackson (The Jackson Laboratory, Bar Harbor, ME).
For tumor protection study, six-to eight-weeks old female C57BL/6 were immunized with the Helios Gene Gun System (Bio-Rad) with 1-2 μg plasmid DNA three times every two weeks as described. Two weeks after the last immunization, mice were challenged s.c. with 1 x10 5 B16 melanoma cells and tumor size was measured (mm 2 ).
Survival between groups was determined using a non-parametric logrank test (BMDP statistical software, Los Angeles, FL).
Preparation of immune effector cells, in vitro activation of T cells
Mice were vaccinated s.c. twice at 3-wk intervals with 10μg human gp100 25-33 or iLR 58-66 peptides, emulsified in 100μl incomplete Freund's adjuvant (IFA). Three weeks after the second vaccination, splenocytes were cultured with 20IU/ml rhIL-2 and 1μg/ml corresponding peptide (mgp100 25-33 and iLR 58-66 , respectively) and used on days 5-7 after the initiation of the culture 17 .
In vivo up take of fusion proteins C57BL/6 mice (4 mice/group) were immunized i.p. twice at 3 wk-intervals using the Helios Gene Gun System (Bio-Rad, Hercules, CA) with 1-2μg of DNA (MIP3α−Dgp100, MIP3α−gp100and mDF2β−gp100) or with 10μg hgp100 25-33 peptide in 100μl
IFA or 100 μl PBS. Three weeks after the second vaccination, splenocytes were harvested, irradiated (2000 Rad) and mixed directly (without any additional protein
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Chemokine receptor binding
The ligand binding-internalization assays were performed with iDC or splenocytes (1x10 5 ) blocked with mouse serum in PBS containing 2% BSA (PBSst). Fusion proteins (10-50μg/ml) were incubated in complete medium for 1h at 37°C or at 4°C.
To detect bound proteins, the cells were incubated with anti-c-myc mAb or isotypematched, purified mouse IgG1, followed with α-mouse Ig-FITC mAb incubation (Jackson ImmunoResearch Laboratory, Bar Harbor, ME) for 20 min each, and then fixed with 1% paraformaldehyde. The binding-internalization was assessed via flow cytometry on a FACScan (Becton Dickinson, Franklin Lakes, NJ) using CellQuest software. 
Confocal microscopy
Results
Chemoattractant fusion proteins retain their functional activity.
We have produced recombinant proteins, which encoded chemokines physically fused with established tumor antigens, including the melanoma-associated antigen, gp100 and tumor-associated embryonic antigen, OFA-iLRP (Fig.1a) . The chemokine moieties used in this study have been selected based on the receptors through which they mediate their biological effects and their selective expression on APC. For example, murine MIP3α/CCL20 target CCR6 preferentially expressed on iDC, while the viral chemokine antagonist, MC148 binds to CCR8 expressed on a variety of APC. Control constructs consisted of either gp100 or OFA antigens alone or fused with an inactive non-CCR8 binding form of MC148 22 . In concordance with our previous reports 11 , each of these chemokine fusion constructs with the gp100 and OFA antigens retained their chemokine receptor binding and signaling properties despite being linked to a relatively large tumor antigen. MIP3α-gp100 and MIP3α-mOFA all specifically bind to CCR6 expressed on bone marrow derived immature DC (BM iDC) (Fig.1b) and on murine splenocytes (SP) (data not shown). Similar to our previous reports 22 , the MC148 fusion proteins bind only to murine BM iDC, but not SP, while the control proteins, namely gp100 or the mutant MC148-D-mOFA, failed to bind any APC population examined (data not shown). While no significant internalization was detected at 4°C, MIP3α-mOFA or MIP3α-gp100 were quickly internalized ( Fig.1b and 1c ) and found intracellularly foci co-localized with lysosomal marker LAMP-1 (Suppl. Fig.1a ) when APC were incubated at 37°C. These data suggest that the fusion proteins not only retained the functional properties of their non-fused chemokine counterparts, but also were efficiently internalized to various intracellular compartments, including lysosomes, where, as we recently reported, chemokine-fused antigens would be processed and presented to MHC Class II molecules 13 . On the other hand, exogenous antigens are known to be poorly taken up and presented to MHC class I, a process known as cross-presentation; therefore, it was interesting to test whether chemokine-mediated internalization would also enable antigen cross-presentation.
Antigen presenting cells efficiently process tumor antigens linked to chemokines
and facilitate peptide presentation through MHC Class I molecules.
MIP3α-fused antigens incubated with APC at non-permissive temperature To examine this possibility, APC derived from naïve C57BL/6 mice were incubated overnight with various concentrations of chemokine-fused gp100 (MIP3α-gp100 or MC148-gp100) after which these cells were irradiated and co-cultured with immune effector cells (splenocytes) derived from C57BL/6 mice immunized with MHC class I epitope peptide of melanoma antigen gp100 (gp100 25-33 peptide). The assumption was that, if APC cross-presented an exogenously added gp100, then they would stimulate MHC class I -specific effector T cells to produce IFN-γ. Indeed, the effector T cells produced significant IFN-γ upon stimulation with syngeneic BM iDC ( Fig.2a) , or SP (Suppl. Fig.1b ) pre-treated with MIP3α-gp100 or MC148-gp100. In contrast, APC treated with gp100 protein alone (gp100 protein) or fused with mutant MC148 protein (MC148-D-gp100) failed to induce IFN-γ production ( Next, to exclude that these effects were only specific to gp100 antigen or dependent on mouse strain (C57BL6), similar studies were performed using fusion The primary responders were MHC class I-dependent CD8 + T cells, since IFN-γ production was significantly reduced in the presence of specific blocking antibodies to MHC H-2 b Class I (Fig.2a) or anti-CD8 molecules (12.3 ± 1.1 pg/ml IFN-γ), but not control isotype matched MAb (213.8 ± 4.1 pg/ml IFN-γ). In support, immune effector cells from pmel-1 mice, which contained >95% transgenic CD8 + T cells (FACS data, not shown) 17 , were also stimulated by APC incubated with MIP3α-gp100 or MC148-gp100, but not with control fusion constructs or gp100 alone (Fig.3) . Overall, these data clearly demonstrate that chemokine-fused antigens, targeted to CCR6 and CCR8 receptors expressed on APC, were processed and crosspresented to MHC class I. This process is quite efficient as APC incubated with as little as 10-100 ng/ml of chemokine-gp100 are capable of stimulating CD8 + T cells in vitro.
Chemokine receptor targeted antigens are also cross-presented in vivo
Next, we examined if the MHC Class I presentation and CD8 + T cell activation described above also occured in vivo in mice injected with chemokine-fused vaccine.
If this is the case, then APC derived from immunized mice alone, in the absence of an additional peptide pulsing, should be capable of stimulating the effector CD8 + T cells from pmel-1 mice. Indeed, as described in Fig.2c , freshly-isolated splenocytes from mice immunized with constructs expressing MIP3α-gp100 induced significant IFN-γ production from the cocultured pmel-1 effector cells (pMIP3α-gp100, p<0.04, Fig.2c ). Splenocytes from mock-treated mice or mice immunized with a gp100 fusion construct containing a mutant MIP3α (which can not bind CCR6) failed to induce any significant IFN-γ production (PBS and pMIP3α-D-gp100, respectively, Fig.2c ). Thus, these data demonstrate that APC are able to take up, process and present antigens to MHC class I in vivo when their chemokine receptors are targeted.
For personal use only. on November 12, 2017. by guest www.bloodjournal.org From Moreover, immunization of C57BL/6 mice with DNA plasmid constructs expressing either MIP3α-gp100 or mDF2β-gp100, but not mutant MIP3α-D-gp100, also elicit a potent MHC Class I-restricted primary T cell response in vivo as splenocytes derived from these animals produce significant levels of IFN-γ upon stimulation with APC pulsed with the mgp100 25-33 peptide, but not with an irrelevant peptide (Suppl. Fig.1c) . In addition, no responses were elicited in control mice treated with a saline (PBS, Suppl. Fig.1c ).
Mechanism of chemoattractant fusion protein cross-presentation: requirement for chemokine receptor endocytosis via clathrin-coated vesicles.
Chemokine receptor endocytosis involves G-protein coupled protein signaling and is mediated through clathrin-coated vesicles utilizing β-arrestin adaptors 5, 6 . Signaling through many GPCRs can be turned off upon treatment with the Gαi inhibitor, pertussis toxin (PTX) 23 , while high sucrose hypertonic solution prevents the assembly of clathrin-coated pits and inhibits receptor-mediated endocytosis 24 . To assess if chemokine fusion constructs have similar requirements to facilitate antigen uptake and presentation, pmel-1 effector T cells were stimulated with iDC derived from naïve C57BL/6 mice treated with chemokine-gp100 fusion proteins in presence or absence of PTX or sucrose. While neither PTX nor sucrose affected T cell stimulation by DC directly pulsed with human gp100 25-33 peptide, T cell activation in response to MIP3α-gp100-and MC148-gp100-treated iDC was completely abrogated with PTX and sucrose treatment (Fig.3a) . Similarly, the MIP3α-mOFA induced crosspresentation was completely abrogated by co-incubation with PTX ( Fig.3b ) and sucrose (data not shown). Therefore, these data not only indicate that the effects are antigen and mouse strain independent, but also further support our initial observation
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Mechanism of cross-presentation of chemokine fusion proteins: requirement for endosomal/lysosomal compartments.
Recently we reported that chemokine receptor-mediated MHC class II presentation was drastically suppressed upon co-incubation with brefeldin A 13 , a fungal metabolite that inhibits vesicle transport of newly synthesized MHC class molecules between the endoplasmic reticulum (ER) and Golgi 25 , and monensin, a sodium/potassium/ proton ionophore that prevents acidification of intracellular compartments and internalization of CCR5 receptors 26 . In the current study, as expected, brefeldin A treatment completely suppressed the CD8 + T cell activation induced by APC incubated with MIP3α-mOFA (Fig.3b) , or MIP3α-gp100 (Fig.3d) . Similarly, T cell responses were also significantly inhibited when APC were treated with agents that affected trafficking or antigen processing within endosomal-lysosomal compartments, namely leupeptin and wortmannin ( Fig.3b and 3d, respectively) . Also, treatment of APC with NH 4 Cl, a weak base which caused a generalized increase in the intracellular pH (Fig.3c) , or bafilomycin A, a highly selective inhibitor of endosome acidification that blocked endosomal ATPase, (data not shown), or chloroquine, the serine and cystein protease inhibitor ( Fig.3b-d ) inhibited T cell activation in response to MIP3α-OFA or mDF2β-OFA. Therefore, taken together with the results from confocal microscopy analysis (Suppl. Fig.1a ), these data suggest that chemokine-mediated crosspresentation required that antigen be first internalized into endosomal and lysosomal compartments. Usually cross-presentation requires that antigen is present in the cytosol and degraded by proteasomes. Therefore, to assess whether chemokine-Ag utilized this pathway, we performed a confocal microscopy study that indicated that MIP3α-Ag was found in the cytosol and co-localized with proteasomes (Fig.1c) . Moreover, T cell stimulation by APC treated with chemokine-Ag (MIP3α-OFA, Fig.3b ; or MIP3α-gp100, Fig.3d) was completely abrogated by co-incubation with lactacystin, a specific inhibitor of proteasomal protein degradation. This is not due to toxic effects of lactacystin as lactacystin treatment failed to affect the T cell stimulatory activity of control APC pulsed with the processed hgp100 25-33 peptide (data not shown), and MHC class II presentation 13 . Therefore, these data suggest that chemokine-Ag are trafficked (from lysosomes, presumably) into the cytosol where they are degraded by proteasomal complexes. The proteasome-degraded peptides are then transported from cytosol to the ER to be associated with MHC class I molecules utilizing TAP-1 machinery.
Therefore, to assess involvement of TAP-1, splenocytes and BM iDC from TAP-1 KO mice were examined for their capacity to cross-present MIP3α-gp100 and stimulate T cells derived from the CD8 + TCR transgenic pmel-1 mice. However, splenocytes or BM iDC from TAP-1 KO mice incubated with MIP3α-gp100 failed to stimulate T cells (Black bars, Fig.4a-b) , while wild type APC facilitated significant IFN-γ expression from pmel-1 effector cells (grey bars, Fig.4a-b) . It should be noted that this difference is not due to the absence of cell surface H-2 b molecules as APC from both mice directly pulsed with hgp100 25-33 , but not an irrelevant peptide stimulated effector cells to produce comparable levels of IFN-γ (Fig.4a-b) .
Immunization with chemokine fusion vaccines induces protective anti-tumor responses
We have previously reported that DNA immunization with constructs expressing chemokine fusions with a non-immunogenic B cell tumor antigen elicited a potent therapeutic anti-tumor immunity against syngeneic B cell lymphoma challenge 11, 12 .
Given that our chemokine fusion constructs with melanoma antigen, gp100, facilitated efficient antigen cross-presentation in vitro, we next examined if vaccination with DNA constructs encoding chemokine fusion protein can induce a protective response in mice challenged with the very aggressive B16 melanoma, which is known for its resistance to CTL 27 . Ten C57BL/6 mice per group were immunized with gene gun three times over a two week interval with constructs expressing gp100 fused with active MIP3α (pMIP3α-gp100) or a mutant MIP3α (pMIP3α-D-gp100), or mock immunized with PBS. Two weeks after the last immunization, mice were challenged subcutaneously with a lethal dose of B16 tumor cells and tumor growth was assessed.
As shown in Fig.5a , a significant inhibition of tumor cell growth was induced by 
Discussion
Here we demonstrate that tumor antigens are efficiently delivered to MHC class I processing and presentation pathways (cross-presentation), if linked with chemokines. The process was independent of chemotaxis, and required only the receptor internalization as both agonist chemokine, MIP3α/CCL19, and antagonist ligand MC148 elicited comparable cross-presentation. In support, we recently The fate of the internalized chemokine during receptor internalization remains unknown, although human CCL3 bound to CCR5 has been shown to recycle back to cell surface 8,30,31 . Our data demonstrates that the fate of the internalized chemokines (chemokine-Ag) is as follows: some proportion of them is degraded in endosomal/lysosomal compartments (for MHC class II presentation) 13 , while the rest escapes to the cytosol where they are degraded by proteasomes to be presented for Requirement for lysosomal proteases may suggest that chemokine-Ag needs to be first pre-processed in the endo/lysosomal compartments, before being transferred to the cytosol to be further degraded by proteasomes. However, the fact that cells can be killed by cytosolic delivery of RNases-linked to chemokines suggest that at least some TAP-independent and NH 4 Cl-sensitive cross-presentation pathways 37, 38 . However, our data demonstrate that chemokine-mediated cross-presentation utilized the classical TAP-dependent MHC class I presentation pathway, since the chemokine fusion-mediated responses were completely blocked with the addition of the specific proteasomal inhibitors, lactacystin; and APC derived from TAP-1 deficient mice were unable to elicit antigen-specific T cell activation. It has been recently postulated that DC present antigens much more efficiently than macrophages due to lower levels of lysosomal proteases 39 ; however, no notable differences were observed in our chemokine-mediated cross-presentation studies (data not shown), suggesting that the fusion-mediated processing does not involve lysosomal degradation.
Tumors express chemokines and, thus, are capable of recruiting APCs (see review 40 ), yet their antigens are not efficiently cross-presented to elicit immunity. As our data suggest, this is presumably due to the fact that the tumor antigen needs to be linked with a functionally active chemokine moiety. In support, we recently demonstrated that mice immunized with a mixture of free chemokine and tumor antigen failed to elicit antigen-specific immune responses indicating that the recruitment of APC alone is not sufficient to induce cross-presentation 12 . This is also due to the fact that most APCs, including LC and skin DCs, primarily deliver exogenous antigens to the MHC class II processing pathway, while cross-presentation was attributed to only CD8 + DC (see review 41 ). However, tumors may not produce the right chemokine needed for attraction of CD8 + DC, or even if they do, crosspresentation often requires large quantities of antigen (mg/ml) 42, 37 . This is a dramatic difference with the chemokine-fused proteins that induce CD8 + T cell responses after being cross-presented at only nmol (ng/ml) quantities. Typically, approaches that target various endocytic cell surface receptors are known to increase the efficiency of antigen presentation between 100-to 10,000-fold 43, 44 .
Cross-presentation alone is not sufficient for induction of antitumor immune responses, rather it can induce tolerance in the absence of cross-priming and other stimuli that activate co-stimulatory molecules B7.1 or CD40 45, 46 (see review 41 ). In this respect, the fact that the same chemokine construct also induced CD4 + T helper (A) Naïve C57BL/6 splenocytes were incubated overnight with 1μg/ml MIP3α-gp100, MC148-gp100, MC148D-gp100 or gp100 protein alone. The cells were subsequently washed, irradiated and then co-cultured with immune effector splenocytes from C57BL/6 mice (immunized with hgp100 25-33 /IFA). IFN-γ release was measured after overnight incubation. Effector cell specificity was validated using splenocytes pulsed with 1μg/ml of hgp100 [25] [26] [27] [28] [29] [30] [31] [32] [33] or an irrelevant A20 peptide; or incubating with B16 melanoma or control A20 lymphoma cells. to be loaded to the MHC class I molecules (9) and exposed on the cell surface, thus, inducing CD8+ T cells (11). ---+  ----------Leupept ine   --+  -----------Chloroquine   -------50 10  1  ----PTX   ----------2.5  ---A20 cell line   -----------+  --M OPC315 cell line   ------------+  -B16 cell line   -------------+ p<0.01
p=0.001
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